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The importance of neuropeptides in the hypo-
thalamus has been experimentally established.
Due to difficulties in assessing function in vivo,
the roles of the fast-acting neurotransmitters
glutamate and GABA are largely unknown. Syn-
aptic vesicular transporters (VGLUTs for glu-
tamate and VGAT for GABA) are required for
vesicular uptake and, consequently, synaptic
release of neurotransmitters. Ventromedial hy-
pothalamic (VMH) neurons are predominantly
glutamatergic and express VGLUT2. To evalu-
ate the role of glutamate release from VMH
neurons, we generated mice lacking VGLUT2
selectively in SF1 neurons (a major subset of
VMH neurons). These mice have hypoglycemia
during fasting secondary to impaired fasting-
induced increases in the glucose-raising pan-
creatic hormone glucagon and impaired induc-
tion in liver of mRNAs encoding PGC-1a and the
gluconeogenic enzymes PEPCK and G6Pase.
Similarly, these mice have defective counterre-
gulatory responses to insulin-induced hypogly-
cemia and 2-deoxyglucose (an antimetabolite).
Thus, glutamate release from VMH neurons is
an important component of the neurocircuitry
that functions to prevent hypoglycemia.
INTRODUCTION
Glutamate and GABA are the major excitatory and inhibi-
tory neurotransmitters in the brain. They exert strong ef-
fects on postsynaptic neurons and are widely distributed.CWith this in mind, it is remarkable how little is known about
their roles in transducing specific behaviors and homeo-
static responses. This is especially true when one con-
siders the hypothalamus, a site where the majority of
focus has been on neuropeptides. Indeed, critically impor-
tant roles have been established for many hypothalamic
neuropeptides and their receptors in regulating food
intake, energy expenditure, insulin-glucose homeostasis,
the sleep-wake cycle, and neuroendocrine output of
the pituitary gland (Cone, 2005; Guillemin, 2005; Saper
et al., 2005; Williams et al., 2004). In striking contrast,
the roles played by fast-acting neurotransmitters such
as glutamate and GABA have been largely unexplored.
This is not because they are thought to be unimportant,
but instead because of the absence ofmethodological ap-
proaches for testing their function in vivo (van den Pol,
2003). The underlying problem limiting investigations is
the widespread distribution of glutamate, GABA, and their
receptors. Because essentially all neurons have receptors
for these neurotransmitters, site-specific injections of
agonists or antagonists invoke responses in all neurons
exposed, generating results of unclear physiologic mean-
ing (van den Pol, 2003). Similarly, total gene knockouts
aimed at disrupting neurotransmitter release or the ability
to respond to neurotransmitters result in complex pheno-
types, many of which are incompatible with life (Fremeau
et al., 2004a; Moechars et al., 2006; Wallen-Mackenzie
et al., 2006; Wojcik et al., 2004, 2006). Thus, there is tre-
mendous need for an approach that allows one to study
the roles of glutamate and GABA in selected sites within
the brain and, hence, in specific behaviors and homeo-
static responses.
Toward these ends, we and others (Wallen-Mackenzie
et al., 2006) have created lox-modified alleles of synaptic
vesicle transporters. In order for a neuron to release gluta-
mate or GABA, the neurotransmitter must first be pack-
aged, at high concentrations, into synaptic vesicles. This
is accomplished by specific transporters, VGLUT1, -2,ell Metabolism 5, 383–393, May 2007 ª2007 Elsevier Inc. 383
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and VGAT in the case of GABA (Gasnier, 2004). It has
previously been demonstrated that knockout of Slc17a7
(Vglut1) (Fremeau et al., 2004a; Wojcik et al., 2004),
Slc17a6 (Vglut2) (Moechars et al., 2006; Wallen-Macken-
zie et al., 2006), and Slc32a1 (Vgat) (Wojcik et al., 2004)
creates neurons that are unable to release their respective
neurotransmitter. By creating lox-modified alleles of these
synaptic vesicle transporters and by crossing such ani-
mals with transgenic mice expressing Cre recombinase
in specific groups of neurons, transsynaptic communica-
tion by these transmitters can be disrupted in a neuron-
specific manner. Such studies make it possible to deter-
mine the role of fast-acting neurotransmitters in specific
behaviors and homeostatic responses.
The ventromedial hypothalamus (VMH) integrates fore-
brain neuronal input with ascending information from the
brainstem and then sends output to regions involved in
control of various behaviors and physiologic responses
(Swanson, 1987). Indeed, VMH neurons send projections
to a vast number of sites, including numerous locations
within themedial hypothalamus, the lateral hypothalamus,
the zona incerta, parts of themidline thalamus, the bed nu-
clei of the stria terminalis, various parts of the amygdala,
and the periaqueductal gray (Canteras et al., 1994; Krieger
et al., 1979; Saper et al., 1976). The VMH also sends pro-
jections, at a lower density, to many other sites, including
direct glutamatergic projection to nearby POMC neurons
(Sternson et al., 2005). By means of these projections,
the VMH is thought to control ingestive, sexual, and defen-
sive behaviors (Canteras, 2002; Choi et al., 2005; King,
2006) and the physiologic responses that accompany
these behaviors, as well as counterregulatory responses
to hypoglycemia (Borg et al., 1994, 1995, 1997). Neurons
in the VMH are largely glutamatergic as evidenced by
high-level expression of mRNA encoding the vesicular
glutamate transporter VGLUT2 and lower levels of expres-
sion of mRNA encoding the vesicular GABA transporter
VGAT and the GABA-synthesizing enzyme glutamic acid
decarboxylase (GAD) (Ovesjo et al., 2001; Ziegler et al.,
2002). The importance of glutamate release from VMH
neurons versus other neurotransmitters and neuropep-
tides in mediating the above-mentioned behaviors and
physiologic responses, however, is unknown.
Steroidogenic factor 1 (SF1, official gene nameNr5a1) is
a member of the nuclear hormone receptor family and, in
the CNS, is expressed exclusively in the VMH (Dhillon
et al., 2006; Stallings et al., 2002). Sf1 knockout mice
have abnormal VMH development and are obese (Majdic
et al., 2002). Recently, we generated Sf1-Cre transgenic
mice that express Cre recombinase selectively in the
VMH (Dhillon et al., 2006). These mice are useful for
VMH-specific knockout of genes flanked by lox sites.
We have used this approach to generate mice lacking lep-
tin receptors (LEPRs) on SF1 neurons (Sf1-Cre;Leprflox/flox
mice). These mice develop mild obesity when fed a chow
diet and become more obese when fed a high-fat diet
(Dhillon et al., 2006). As mentioned above, the relevant
mediator released by SF1 neurons is largely unknown. In384 Cell Metabolism 5, 383–393, May 2007 ª2007 Elsevier Inc.the present study, we evaluated the role of glutamate
by generating mice that lack VGLUT2 selectively in SF1
neurons (Sf1-Cre;Vglut2flox/flox mice).
RESULTS
Generation of Vglut2flox/flox Mice
Gene targeting in ES cells was used to createmicewith lox
sites flanking exon 2 of the Vglut2 gene (Figure 1A). Cre
recombinase-mediated deletion of exon 2 is expected to
generate a null Vglut2 allele, as exon 1 contains only
5% of VGLUT2’s coding sequence. Furthermore, the
reading frame is disrupted if exon 1 splices to exon 3. To
confirm the null status of this allele, we generated mice
homozygous for the deleted allele. The deleted allele
was first created by crossing Vglut2+/flox mice with trans-
genic animals expressing Cre in the female germline
(ZP3-Cre mice; The Jackson Laboratory, stock #003651).
Female ZP3-Cre;Vglut2+/flox mice were then used to gen-
erate offspring that were heterozygous for the deleted
allele (Vglut2+/ mice). These heterozygotes (Vglut2+/)
were then bred to generate homozygous, presumably
null animals (Vglut2/). Prior studies have demonstrated
that mice lacking VGLUT2 are not viable (Moechars
et al., 2006; Wallen-Mackenzie et al., 2006). Consistent
with this, we were unable to detect any homozygous off-
spring at age 3 weeks (out of 31 offspring genotyped, 10
were Vglut2+/+, 21 were Vglut2+/, and 0 were Vglut2/).
However, we were able to detect offspring homozygous
for the deleted allele at embryonic day 19 (out of 10 em-
bryos genotyped, 3 were Vglut2+/+, 5 were Vglut2+/,
and 2 were Vglut2/). RT-PCR using mRNA isolated
from brain tissue of Vglut2+/ mice confirmed that exon
2 was missing and that exon 1 was spliced to exon 3.
These results demonstrate that the Cre-mediated deletion
of the Vglut2flox allele results in a null allele.
Figure 1. Generation of Mice lacking VGLUT2 in SF1 Neurons
(A) The Vglut2 gene, the Vglut2flox allele, and the Cre-deleted Vglut2
null allele. E, exon; Cre, Cre recombinase.
(B) In situ hybridization for Vglut2 mRNA. Scale bar = 100 mM.
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To generate mice lacking VGLUT2 in SF1 neurons, as well
as control mice, Vglut2flox/flox mice were crossed with
Sf1-Cre;Vglut2flox/flox mice. To test for neuron-specific
loss of Vglut2 mRNA, in situ hybridization was performed
using a riboprobe corresponding to exon 2. As previously
observed (Ziegler et al., 2002), Vglut2mRNA is abundantly
expressed in the VMH of control mice (Figure 1B, left
panel). As expected, Vglut2 mRNA is selectively absent
in the VMH of Sf1-Cre;Vglut2flox/flox mice (Figure 1B, right
panel). In contrast, Vglut2 mRNA is undisturbed in all
other brain regions of Sf1-Cre;Vglut2flox/flox mice (data
not shown). We were unable to detect VMH expression
of Vglut1 mRNA or Vglut3 mRNA in control (Vglut2flox/flox
mice) or VMH-deleted (Sf1-Cre;Vglut2flox/flox) mice (see
Figure S1 in the Supplemental Data available with this
article online). Thus, in Sf1-Cre;Vglut2flox/flox mice, Vglut2
mRNA is undetectable in the VMH and there is no
compensatory upregulation of Vglut1 or Vglut3 mRNA.
Glutamate Release Is Disrupted in SF1 Neurons
of Sf1-Cre;Vglut2flox/flox Mice
To confirm that deletion of VGLUT2 in SF1 neurons leads
to loss of glutamate release, we performed electrophysio-
logic recordings (whole-cell, voltage-clamp mode) on SF1
neurons, plated at low density, that had formed autosy-
napses (autaptic cultures) (Hentges et al., 2004). To permit
identification of SF1 neurons, Sf1-Cre transgenic mice
were first crossed with animals bearing a Cre-dependent
GFP reporter transgene (Z/EG; The Jackson Laboratory)
(Novak et al., 2000). Control neurons were derived from
Sf1-Cre;Z/EG mice, while VGLUT2-deleted neurons
were derived from Sf1-Cre;Z/EG;Vglut2flox/floxmice. Excit-
atory (mediated by glutamate) and inhibitory (mediated by
GABA) postsynaptic currents (EPSCs and IPSCs) were
evoked every 20 s by depolarizing pulses (from a holding
potential of 60 mV to +10 mV for 2 milliseconds). With
the conditions utilized (see Experimental Procedures),
both EPSCs and IPSCswere identified as inward currents.
Glutamate-mediated EPSCs versus GABA-mediated
IPSCs were differentiated based upon decay time con-
stants (0.8–3.0 ms for EPSCs and 10–15 ms for IPSCs)
and effects of glutamate receptor and GABA receptor an-
tagonists. Out of 12 control SF1 neurons, 8 neurons were
found to have EPSCs mediated by glutamate (Figure 2A),
while 2 neurons were found to have IPSCs mediated by
GABA (Figure 2B, results summarized in Figure 2C). Two
neurons lacked EPSCs or IPSCs, indicating that they
release neither glutamate nor GABA, or that they failed
to establish functional autosynapses. These results indi-
cate that most SF1 neurons are glutamatergic while
a smaller percentage are GABAergic. Of interest, out of
11 SF1 neurons from Sf1-Cre;Z/EG;Vglut2flox/flox mice,
0 neurons were found to have EPSCs, while 2 neurons
were found to have IPSCs mediated by GABA (results
summarized in Figure 2C). These findings indicate that,
as expected, glutamate release is selectively disrupted
in SF1 neurons of Sf1-Cre;Vglut2flox/flox mice.CCell Bodies and Projections of SF1 Neurons
in Sf1-Cre;Vglut2flox/flox Mice
It is conceivable that disruption of glutamatergic transmis-
sion could alter the survival and/or projections of SF1 neu-
rons. To address this, we compared the density of cell
bodies and projections of control (Sf1-Cre;Z/EG) and
VGLUT2-deleted (Sf1-Cre;Z/EG;Vglut2flox/flox) SF1 neu-
rons. The SF1 neurons and their projections were identi-
fied by immunohistochemical detection of GFP in brain
sections of 10-week-old mice. These studies indicated
that the density of SF1 cell bodies in the VMH was un-
changed in Sf1-Cre;Z/EG;Vglut2flox/flox mice (Figure S2A).
To check for projections, we examined the bed nuclei of
stria terminalis and the periaqueductal gray area, two sites
that are densely innervated by VMH neurons. These anal-
yses indicated that projections were not grossly disturbed
in Sf1-Cre;Z/EG;Vglut2flox/flox mice (Figure S2B). In total,
these studies indicate that glutamatergic transmission is
not required for the survival of SF1 neurons or for the
development of their projections.
Body Weight in Sf1-Cre;Vglut2flox/flox Mice
Sf1-Cre;Vglut2flox/flox mice fed a standard chow diet had
normal body weights (data not shown). However, when
fed a high-fat, high-sucrose diet, Sf1-Cre;Vglut2flox/flox
mice developed a modest increase in body weight com-
pared with controls (Vglut2flox/flox mice) (Figure 3A). This
was associated with a small increase in food intake (Fig-
ure 3B) and fat stores (Figure 3C) but not with an obvious
effect on energy expenditure (Figure 3D).These results
suggest that release of glutamate from SF1 neurons plays
Figure 2. Assessment of Neurotransmitter Release in
Autaptic Cultures
Control SF1 neurons were prepared from Sf1-Cre;Z/EG mice, and
VGLUT2-deficient SF1 neurons were prepared from Sf1-Cre;Z/EG;
Vglut2flox/flox mice.
(A) Excitatory postsynaptic current from a control SF1 neuron recorded
in the absence and then presence of glutamate receptor antagonists
(CNQX and APV).
(B) Inhibitory postsynaptic current from a control SF1 neuron recorded
in the absence and then presence of a GABA receptor antagonist
(bicuculline).
(C) Summary of recordings from control (Sf1-Cre;Z/EG) and VGLUT2-
deficient (Sf1-Cre;Z/EG;Vglut2flox/flox) SF1 neurons.ell Metabolism 5, 383–393, May 2007 ª2007 Elsevier Inc. 385
Cell Metabolism
Glutamate Release by VMH Neuronslittle or no role in the case of chow-fed mice and a small
role in the case of fat-fed mice in regulating energy
balance.
Impaired Glucose Homeostasis in the Fasted State
Sf1-Cre;Vglut2flox/floxmice had lower blood glucose levels,
comparedwith Vglut2flox/flox controls, after fasting for 24 hr
(55 ± 3 versus 68 ± 5 mg/dl in males, Figure 4A; 53 ± 2
versus 67 ± 5 mg/dl in females, Figure 4B). Insulin values
fell with fasting in both groups and were similar in Sf1-
Cre;Vglut2flox/flox mice versus Vglut2flox/flox mice in both
the fed and fasted states (data not shown). In contrast,
Sf1-Cre;Vglut2flox/flox mice had an impaired fasting-me-
diated increase in the pancreatic hormone glucagon
(Figure 4C). Glucagon works on the liver, where it stimu-
lates glycogenolysis (breakdown of glycogen to glucose)
and gluconeogenesis (synthesis of glucose from pyruvate,
lactate, glycerol, and amino acids) (Vidal-Puig and O’Ra-
hilly, 2001). The effect on gluconeogenesis is mediated
in part by augmenting expression of PGC-1a, a transcrip-
tion coactivator that stimulates expression of genes
encoding gluconeogenic enzymes such as glucose-6-
phosphatase (G6Pase) and phosphoenolpyruvate car-
boxykinase (PEPCK) (Yoon et al., 2001). As expected, in
livers of control Vglut2flox/flox mice, fasting increased
expression of Ppargc1a (PGC-1a), Pck1 (PEPCK), and
G6pc (G6Pase) mRNAs (Figures 4D–4F). Of note, these
fasting-induced increases in gene expressionwere absent
in livers of Sf1-Cre;Vglut2flox/flox mice. These findings
indicate that hypoglycemia during fasting in Sf1-Cre;
Vglut2flox/flox mice is mediated at least in part by failure
to increase blood glucagon levels and subsequent failure
Figure 3. Effect of High-Fat, High-Sucrose Diet on Energy
Balance
Male mice (n = 8–10 mice per group) were studied. The high-fat, high-
sucrose diet (HFD) was started at the age of 8–10 weeks. In this and all
other figures, error bars represent ±SEM. *p < 0.05.
(A) Body weight.
(B) Cumulative food intake.
(C) Body composition.
(D) Energy expenditure as assessed by oxygen consumption.386 Cell Metabolism 5, 383–393, May 2007 ª2007 Elsevier Into induce hepatic expression of PGC-1a and its gluconeo-
genic targets, G6Pase and PEPCK.
Impaired Counterregulation of Insulin-Induced
Hypoglycemia
Acute administration of insulin induces hypoglycemia.
Counterregulatory measures, initiated in part by the
brain, operate to limit the degree of hypoglycemia. As
shown in Figure 5A, a single dose of insulin (1.5 U/kg) at
60 min caused a greater fall in blood glucose in Sf1-Cre;
Vglut2flox/flox mice. This greater degree of hypoglycemia
was associated with an impaired glucagon response
(Figure 5B).
To confirm these findings, we performed hypoglycemic
clamp studies, in which hypoglycemia is induced and sus-
tained at similar levels in a controlled fashion (Figure 5C).
Sf1-Cre;Vglut2flox/flox mice tended to require higher rates
of glucose infusion during the clamp, which is consistent
with decreased rates of endogenous glucose production
(Figure 5D). Of note, hypoglycemia induced a large in-
crease in plasma glucagon levels in control mice, and,
importantly, this response was undetectable in Sf1-Cre;
Vglut2flox/flox mice (Figure 5E). Similarly, hypoglycemia
induced a large increase in blood levels of epinephrine in
control mice, and this response was blunted in Sf1-Cre;
Vglut2flox/flox mice (Figure 5F). In total, these results dem-
onstrate that Sf1-Cre;Vglut2flox/flox mice have an impaired
Figure 4. The Effects of Twenty-Four Hours of Fasting on
Blood Glucose, Glucagon, and Liver Gene Expression
Male and female mice (n = 13–15 per group), age 8–10 weeks, were
studied. *p < 0.05; **p < 0.01.
(A) Blood glucose in male mice.
(B) Blood glucose in female mice.
(C) Plasma glucagon in female mice.
(D–F) PGC-1a, PEPCK, and G6Pase mRNA levels in livers from
female mice.c.
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glycemia.
Impaired Counterregulatory Response to Central
2-Deoxyglucose
2-deoxyglucose (2-DG) is a nonmetabolizable glucose
analog that inhibits glucose metabolism in cells. Injection
of 2-DG into the third ventricle of the brain is frequently
used as a means of mimicking central glucopenia (Borg
et al., 1995;Miki et al., 2001). Thismanipulation isuseful be-
cause ‘‘glucopenia’’ is limited to thebrain andalsobecause
it is not confoundedby thepresenceof hyperinsulinemia. In
control mice, central 2-DG treatment for 30 min increased
blood glucose levels (Figure 6A), plasma glucagon levels
(p = 0.06) (Figure 6B), and PEPCKmRNA levels in the liver
(Figure 6C). Therewas also a trend forG6PasemRNA to in-
crease (Figure 6D). All of these responses to central 2-DG
Figure 5. Effects of Insulin-Induced Hypoglycemia on Coun-
terregulatory Response
For the single-injection study (A and B), male mice (n = 12–15), age 10–
12 weeks, were fasted overnight and then given a single dose of insulin
(1.5 U/kg). For the hyperinsulinemic-hypoglycemic clamp studies
(C–F), male mice (n = 5–10), age 12–14 weeks, were used. Insulin
infusion started at time 0 and continued during the entire 90min period.
Glucose was infused at a variable rate with the goal of maintaining
glucose at approximately 45 mg/dl. *p < 0.05.
(A) Blood glucose at 60 min.
(B) Plasma glucagon at 60 min.
(C) Blood glucose levels during clamp.
(D) Glucose infusion rate (GIR) during the clamp.
(E) Rise in glucagon (increase at 60–90 min interval over level observed
at time 0).
(F) Rise in epinephrine (increase at 60–90 min interval over level
observed at time 0).were absent in Sf1-Cre;Vglut2flox/flox mice. These results
demonstrate that counterregulatory responses to central
glucopenia are defective in Sf1-Cre;Vglut2flox/flox mice.
However, some counterregulatory responses may be
normal in Sf1-Cre;Vglut2flox/flox mice. Peripheral 2-DG ad-
ministration is also known to stimulate food intake (Ritter
et al., 2006; Sindelar et al., 2004), which functions to raise
blood glucose levels. The hyperphagic response to fasting
or 2-DG was preserved in Sf1-Cre;Vglut2flox/flox mice (see
Figure S3). These results suggest that glutamate release
from SF1 neurons is not involved in the pathway by which
central glucopenia stimulates food intake.
Induction of c-Fos in the Dorsal Motor Nucleus
of the Vagus
Induction of c-Fos is a well-established indicator of neuro-
nal activation (Herrera and Robertson, 1996). SF1 neurons
release glutamate, which is an excitatory neurotransmit-
ter, and this release is required for the glucagon response
to hypoglycemia. Thus, there is an excitatory efferent
pathway from SF1 neurons to pancreatic a cells. Neurons
situated in this pathway activated (directly or indirectly) by
glutamate released from SF1 neurons could be identified
by comparing hypoglycemia-mediated c-Fos induction
in Vglut2flox/floxmice versus Sf1-Cre;Vglut2flox/floxmice. In-
deed, significantly more neurons express c-Fos in the dor-
sal motor nucleus of the vagus (DMV) of three consecutive
Figure 6. Effect of Centrally Administered 2-Deoxyglucose on
Blood Glucose, Glucagon, and Liver Gene Expression
Female mice (n = 9–10 per group), age 10 weeks, were studied. 2-
deoxyglucose (2-DG) or saline was administered i.c.v. *p < 0.05.
(A) Blood glucose was assessed at 0 and 30 min after saline or 2-DG
treatment.
(B) Glucagon was assessed 30 min after saline or 2-DG treatment.
(C and D) PEPCK and G6PasemRNA levels in the liver were assessed
30 min after saline or 2-DG treatment.Cell Metabolism 5, 383–393, May 2007 ª2007 Elsevier Inc. 387
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Motor Nucleus of the Vagus
Sixty minutes after treatment with saline or in-
sulin (1.5 U/kg), brains from Vglut2flox/flox and
Sf1-Cre;Vglut2flox/flox mice were removed and
immunostained for c-Fos. The saline-treated
Vglut2flox/flox and Sf1-Cre;Vglut2flox/flox mice
were pooled together as controls since c-Fos
induction was not different between these
mice. Three consecutive sections immediately
rostral to the area postrema were analyzed.
(n = 8 for control group; n = 4 for other groups.)
Scale bar = 100 mM.
(Aa–Ac) c-Fos expression in saline-treated
mice.
(Ba–Bc) c-Fos expression in insulin-treated
Vglut2flox/flox mice.
(Ca–Cc) c-Fos expression in insulin-treated
Sf1-Cre;Vglut2flox/flox mice.
(D) Summary of c-Fos-positive neurons in DMV
nuclei.sections immediately rostral to the area postrema in insu-
lin-treated hypoglycemic Vglut2flox/flox mice (18 ± 2.0/
DMV/section; Figures 7Ba–7Bc and 7D) compared to
saline-treated mice (1.4 ± 0.1/DMV/section; Figures
7Aa–7Ac and 7D). In contrast, in insulin-treated Sf1-Cre;
Vglut2flox/flox mice, the induction of c-Fos is significantly
reduced (11 ± 1.7/DMV/section; Figures 7Ca–7Cc and
7D). Thus, it is likely that DMV neurons act as a link
between SF1 neurons and pancreatic a cells.
DISCUSSION
Neuropeptides versus Fast-Acting
Neurotransmitters
Important questions exist regarding roles of neuropep-
tides versus the fast-acting neurotransmitters glutamate
and GABA in regulating hypothalamic responses (van
den Pol, 2003). Neuropeptides and neurotransmitters
may both function as independent transmitters, or, alter-
natively, neuropeptides may work by modulating the ac-
tions of glutamate and GABA. Key insight into the function
of neuropeptides has been gained through the administra-
tion of agonists and antagonists, as well as the targeted
disruption of genes encoding neuropeptides and their re-
ceptors. In contrast, with regards to assessing the roles of
glutamate and GABA in hypothalamic function, these
approaches have not been (or would not be) particularly
informative. Thus, the role of fast-acting neurotransmitters
in regulating hypothalamic function in vivo is largely un-
known. Based upon the results of brain slice electrophys-
iology studies, it is likely that fast-acting neurotransmitters388 Cell Metabolism 5, 383–393, May 2007 ª2007 Elsevier Inc.play important roles (Cowley et al., 1999, 2001; van den
Pol, 2003). A major goal of the present study was to
develop an approach for studying, in vivo, their roles in
regulating behaviors and physiologic processes.
Toward these ends, we have used neuron-specific
knockout of the vesicular glutamate transporter VGLUT2
to assess the role of glutamate. VGLUT2, but not VGLUT1
or VGLUT3, is expressed in the hypothalamus (Gras et al.,
2002; Ziegler et al., 2002). The present study focused on
the VMH, a site that is rich in glutamatergic neurons and
thought to play important roles in controlling an array of
behaviors and physiologic responses (Swanson, 1987).
Specifically, we used Cre/lox technology to generate mice
that lack VGLUT2 in SF1 neurons (Sf1-Cre;Vglut2flox/flox
mice). SF1 neurons constitute the majority of VMH neu-
rons (Stallings et al., 2002). Electrophysiologic studies
confirmed that glutamatergic transmission bySF1neurons
was completely disrupted by this approach (Figure 2C).
Thus, Sf1-Cre;Vglut2flox/floxmice should be extremely use-
ful for determining the function of glutamate release by
VMH neurons. This general approach (neuron-specific de-
letion of vesicular transporters) and the generated mouse
lines (for example, Vglut2flox/flox mice) should have broad
applicability to studieswhere the goal is to link neurotrans-
mission by selected neurons with specific behaviors and
physiologic responses.
Counterregulatory Response to Hypoglycemia
and the Role of the Brain
The brain requires a continuous supply of glucose for
proper function and survival. To prevent hypoglycemia,
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(Cryer, 2005): (1) insulin secretion by pancreatic b cells
decreases; (2) glucagon secretion by pancreatic a cells
increases; (3) if needed, epinephrine secretion by the
adrenal medulla gland increases; and (4) food intake is
stimulated. Reduced insulin secretion is thought to be
a direct response of b cells to low blood glucose. The other
responses, however, are driven primarily by the brain.
These critically important countermeasures are initiated
by fasting, and iatrogenically, when hypoglycemia de-
velops following insulin treatment. Indeed, insulin-induced
hypoglycemia complicates and severely limits the wide-
spread application of intensive insulin therapy in type 1
diabetes, which has been shown to markedly reduce
microvascular complications of chronic hyperglycemia
(Cryer, 2005). This issue is further exacerbated by the
fact that counterregulatory responses to hypoglycemia
are defective in individuals with diabetes (Cryer, 2005).
For this reason, understanding the mechanisms responsi-
ble for counterregulatory responses and the reasons why
they are inoperative in diabetics is an extremely important
area for investigation.
The CNS detects hypoglycemia and then initiates coun-
terregulatory responses. The brain contains ‘‘glucose-
excited’’ neurons (whose firing rate increases as glucose
levels rise) and ‘‘glucose-inhibited’’ neurons (whose firing
rate increases as glucose levels fall) (Anand et al., 1962;
Burdakov et al., 2005b; Oomura et al., 1974; Routh,
2002). Glucose depolarizes glucose-excited neurons by
closing ATP-sensitive K+ channels (Ashford et al., 1990;
Miki et al., 2001; Routh, 2002). The mechanism by which
glucose hyperpolarizes glucose-inhibited neurons, on the
other hand, is less well understood, but it may involve al-
tered activity of chloride channels (Routh, 2002) or Na/K
pumps (Silver and Erecinska, 1998), or could also involve
tandem-pore K+ (K2p) channels, as was recently shown
for glucose-inhibited orexin neurons (Burdakov et al.,
2006). Neurons capable of sensing glucose are abundant
in various parts of the hypothalamus (including the VMH,
the lateral hypothalamus, and the arcuate nucleus) and in
the hindbrain (Burdakov et al., 2005a; Ibrahim et al.,
2003; Marty et al., 2005; Muroya et al., 1999; Ritter et al.,
2006; Routh, 2002). In principle, the method employed
by the brain to detect hypoglycemia could involve de-
creasedactivity of glucose-excited neurons, increased ac-
tivity of glucose-inhibited neurons, input from peripheral
blood glucose sensors (Burcelin et al., 2000), or possibly
some combination of these three processes.
The Role of the VMH
The neurocircuitry underlying detection of hypoglycemia
and subsequent counterregulatory responses is not well
known. The VMH is believed to play a role for the following
reasons: (1) the VMH contains neurons capable of sensing
glucose (Ashford et al., 1990; Routh, 2002); (2) local gluco-
penia in the VMH induced by infusion of 2-DG produces
counterregulatory responses (Borg et al., 1995); (3) lesions
of the VMH impair counterregulatory responses (Borg
et al., 1994); and (4) infusion of glucose directly into theVMHduring systemic hypoglycemia attenuates counterre-
gulatory responses (Borg et al., 1997).While these findings
implicate the VMH, they are limited by uncertainty regard-
ing the rangeofdiffusionof infusedmolecules (glucoseand
2-DG) and the extent of ablative lesions. Of note, glucose-
excited (POMC and MCH) neurons and glucose-inhibited
(NPY/AGRP and orexin) neurons are found nearby in the
arcuate nucleus and the lateral hypothalamus (Burdakov
et al., 2005a; Ibrahim et al., 2003; Muroya et al., 1999).
In the present study, we have shown that Sf1-Cre;
Vglut2flox/flox mice have clear defects in counterregulatory
responses. This manifests itself as hypoglycemia during
fasting and insulin treatment and as a defective hypergly-
cemic response to neuroglycopenia (induced by central
infusion of 2-DG). The greatest counterregulatory defect
was seen in hypoglycemia-induced secretion of glucagon.
A modest impairment was seen in hypoglycemia-induced
secretion of epinephrine. Of note, no impairment was seen
in the hyperphagic response to neuroglycopenia. This
latter finding is in agreement with studies implicating hind-
brain catecholaminergic cell groups with projection to the
PVH (Ritter et al., 2006) and neuropeptide Y (Sindelar
et al., 2004), which is not found in the VMH, in mediating
neuroglycopenia-induced hyperphagia. In total, the pres-
ent study definitively establishes a role for SF1 neurons
and glutamate release by these neurons in the homeo-
static neurocircuitry that prevents hypoglycemia.
Afferents and Efferents of SF1 Neurons
The ‘‘first-order neurons’’ responsible for detecting hypo-
glycemia have not been identified. They could be the SF1
neurons themselves. A subset of VMH neurons are known
to sense glucose (Song and Routh, 2005), some of which
could be SF1 neurons. Alternatively, it is possible that the
primary ‘‘glucose-sensing’’ neurons are upstream of SF1
neurons. One possibility is that the hindbrain catechol-
aminergic neurons sense glucose. These neurons are re-
sponsive to hypoglycemia and send projections to the
VMH (Ritter et al., 2006). Consistent with this, the norepi-
nephrine level is increased in the VMH area in response to
hypoglycemia (Beverly et al., 2001), and VMH neurons ex-
press adrenergic receptors (Boundy and Cincotta, 2000).
Another possibility is that the orexin neurons in the lateral
hypothalamus sense glucose; these neurons have been
shown to be excited by low glucose (Burdakov et al.,
2005a, 2006). Orexin receptors 1 (OX1R) and 2 (OX2R)
are both expressed at high levels in the VMH (Marcus
et al., 2001). Other neurons, including glucose-excited
POMC neurons and MCH neurons or glucose-inhibited
NPY/AGRP neurons, could also be upstream of SF1 neu-
rons (Burdakov et al., 2005a; Ibrahim et al., 2003; Muroya
et al., 1999; Ritter et al., 2006). Likewise, it is possible that
peripheral glucose sensors (Burcelin et al., 2000) could
provide input to the VMH. Identifying the primary site re-
sponsible for detecting hypoglycemia and determining
how this site connects with SF1 neurons is an important
area of investigation.
Similarly, the efferent pathways connectingSF1neurons
withglucagonsecretion are alsoof interest. TheautonomicCell Metabolism 5, 383–393, May 2007 ª2007 Elsevier Inc. 389
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tantly, blockade of parasympathetic and sympathetic in-
put to pancreatic a cells prevents hypoglycemia-induced
and neuroglycopenia-induced increases in glucagon
(Rossi et al., 2005; Taborsky et al., 1998). Given this, para-
sympathetic preganglionic neurons in the DMV and sym-
pathetic preganglionic neurons in the spinal cord could
be downstream of SF1 neurons. Consistent with an impor-
tant role for parasympathetic preganglionic neurons, we
have found that hypoglycemia-mediated induction of
c-Fos in the DMV at the level of the area postrema is signif-
icantly attenuated in Sf1-Cre;Vglut2flox/flox mice (Figure 7).
This finding is likely to be relevant since DMV neurons at
this level send direct projections to the pancreas (Rinaman
and Miselis, 1987). How SF1 neurons connect with DMV
neurons, however, remains to bedetermined. The connec-
tion may be indirect since direct projections from the VMH
to theDMVhave yet to bedescribed (Canteras et al., 1994).
Body Weight and Release of Glutamate from SF1
Neurons
Mice homozygous for a disrupted Sf1 allele andmice lack-
ing leptin receptors on SF1 neurons (Sf1-Cre;Lepr flox/flox
mice) are modestly obese when fed a chow diet and
develop marked obesity when fed a high-fat diet (Dhillon
et al., 2006; Majdic et al., 2002). With this in mind, it is
surprising that Sf1-Cre;Vglut2flox/flox mice do not become
obese when fed a chow diet and have very limited obesity
when fedahigh-fat diet. These findings raise thepossibility
that some other effector released from SF1 neurons, for
example BDNF (Xu et al., 2003) or GABA (as shown in Fig-
ure 2, some SF1 neurons are GABAergic), may play a role
in regulating body weight. We suspect that BDNF release
from SF1 neurons is not involved since mice lacking
BDNF in SF1 neurons (Sf1-Cre;Bdnf flox/flox mice) failed to
develop obesity (data not shown).We are presently testing
the role of GABA by assessing energy homeostasis in
Sf1-Cre;Vgat flox/flox mice.
Summary
This study demonstrates that neuron-specific manipula-
tion of vesicle neurotransmitter transporters, such as
VGLUT2, is a useful means of linking fast-acting neuro-
transmitter release with specific functions. In addition, we
have established that SF1 neurons in the VMH and gluta-
mate release by these neurons are important components
of the neurocircuitry that functions to prevent hypoglyce-
mia. Using SF1 neurons as a starting point, it will be impor-
tant to identify the afferent and efferent components of this
circuitry. Knowledge of these pathways should provide
a framework for studies aimed at understanding the clini-
cally significant problem of defective counterregulatory
responses to hypoglycemia in individuals with diabetes.
EXPERIMENTAL PROCEDURES
Animal Care
All animal care and experimental procedures were approved by the
Beth Israel Deaconess Medical Center Institutional Animal Care and390 Cell Metabolism 5, 383–393, May 2007 ª2007 Elsevier Inc.Use Committee. Mice were housed at 22C–24C with a 14 hr light/
10 hr dark cycle with standard mouse chow (Teklad F6 Rodent Diet
8664; 4.05 kcal/g, 3.3 kcal/g metabolizable energy, 12.5% kcal from
fat; Harlan Teklad) and water provided ad libitum.
Generation of Vglut2flox/flox Mice and Sf1-Cre;Vglut2flox/flox Mice
The lox-modified Vglut2 (Slc17a6) targeting construct was constructed
using a mouse 129 BAC genomic clone and recombineering technol-
ogy (Lee et al., 2001). The two loxP sites were inserted in the first intron
and the second intron, respectively.
Sf1-Cre;Vglut2+/flox mice were generated by mating Sf1-Cre trans-
genic mice (FVB/N background) (Dhillon et al., 2006) with Vglut2+/flox
mice (129, C57BL/6 background), and study subjects were generated
by mating Sf1-Cre;Vglut2flox/flox mice with Vglut2flox/flox mice. See
Supplemental Experimental Procedures for details.
High-Fat, High-Sucrose Diet Study
Groups of 8- to 10-week-old male controls (Vglut2flox/flox mice) and
Sf1-Cre;Vglut2flox/flox mice were switched to a high-fat, high-sucrose
diet (HFD) and maintained on HFD for 12 weeks. See Supplemental
Experimental Procedures for study details.
Electrophysiologic Recordings on Autaptic Cultured Neurons
Micropunched VMH tissues were digested using a papain dissociation
system (Worthington Biochemical Corporation). Digested neurons
were seeded on poly-L-lysine-coated glass coverslips in Neurobasal
A medium (Invitrogen). The neurons were planted at low density to
encourage the formation of autosynapses.
Synaptic currents were recorded in whole-cell voltage-clampmode,
and release of synaptic vesicles was evoked by a depolarizing pulse
to +10 mV from the holding potential of 60 mV, applied every 20 s.
The solution used in the recording pipette permits identification of
both glutamatergic EPSCs and GABAergic IPSCs as inward current.
EPSCs and IPSCs were identified by their deferent decay time con-
stants and by using specific glutamate receptor (QBNX and D-APV)
and GABA receptor (bicuculline) antagonists. See Supplemental
Experimental Procedures for details.
In Situ Hybridization Studies
In situ hybridizations were performed as previously described (Kishi
et al., 2003). See Supplemental Experimental Procedures for details.
Glucose Homeostasis Studies
Fed blood glucose levels were measured between 9 a.m. and 10 a.m.
Fasted blood glucose, liver gluconeogenic gene expression, and
glucagon levels were measured after 24 hr fasting.
For the insulin-induced hypoglycemia study, overnight-fasted males
were administrated i.p. with saline or insulin at 1.5 U/kg. At 1 hr after
administration, blood was collected for determination of various
parameters.
For i.c.v. injections, a stainless-steel cannula (30 gauge) was
implanted in the right lateral ventricle. On the test day, 2-deoxyglucose
(1 mg/3 ml vol/mouse) or saline was injected i.c.v. into fed mice. At 30
min after injection, liver samples were collected, and glucose, insulin,
and glucagon were determined. See Supplemental Experimental
Procedures for details.
Quantitative PCR Assay
Liver RNA was reverse transcribed with RETROscript (Ambion, Inc.)
and amplified using Assay-on-Demand TaqMan probes and primers
(Applied Biosystems). Quantitative PCR was performed on an
Mx4000 instrument (Stratagene). See Supplemental Experimental
Procedures for details.
Hyperinsulinemic-Hypoglycemic Clamp Studies
The hyperinsulinemia-hypoglycemia protocol was a modification of
a procedure previously described for rats (McCrimmon et al., 2006).
Briefly, at t = 0, a 90 min 10 mU/kg/min infusion of human regular
Cell Metabolism
Glutamate Release by VMH Neuronsinsulin (Eli Lilly) was begun. Glucose was allowed to fall to 45 mg/dl
and was then maintained at this level for 60–90 min. Samples for mea-
surement of the hormones epinephrine, norepinephrine (HPLC with
electrochemical detection), and glucagon (RIA, Linco Research Inc.)
were taken at 0, 60, and 90 min. See Supplemental Experimental
Procedures for details.
Hypoglycemia-Mediated c-Fos Induction
Vglut2flox/flox and Sf1-Cre;Vglut2flox/flox mice were acclimated for 7
days before i.p. injection of either saline (four mice from each geno-
type) or insulin (1.5U/kg, fourmice from each genotype). Blood glucose
was then monitored, and the mice were transcardially perfused at 60
min. The brains were cut in five series with 25 mM thickness and immu-
nostained for c-Fos with a-c-Fos (catalog # PC38 [Calbiochem] raised
in rabbit at 1:25,000).
In the DMV, the greatest induction of c-Fos was observed in three
consecutive sections immediately rostral to the appearance of the
area postrema in Vglut2flox/flox mice. Therefore, c-Fos-positive neu-
rons were counted in the DMV of these sections. The saline-treated
Vglut2flox/flox mice and Sf1-Cre;Vglut2flox/flox mice were pooled to-
gether as a saline control, as there was no difference in c-Fos induction
in these mice. Only neurons showing clear, round c-Fos-stained nuclei
were counted as positive for c-Fos.
Statistical Methods
Data sets were analyzed for statistical significance using Prism
(GraphPad) for a two-tailed unpaired Student’s t test.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, and three figures and can be found with
this article online at http://www.cellmetabolism.org/cgi/content/full/
5/5/383/DC1/.
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